AU2019223130B2 - Botulinum neurotoxin biohybrid - Google Patents

Botulinum neurotoxin biohybrid Download PDF

Info

Publication number
AU2019223130B2
AU2019223130B2 AU2019223130A AU2019223130A AU2019223130B2 AU 2019223130 B2 AU2019223130 B2 AU 2019223130B2 AU 2019223130 A AU2019223130 A AU 2019223130A AU 2019223130 A AU2019223130 A AU 2019223130A AU 2019223130 B2 AU2019223130 B2 AU 2019223130B2
Authority
AU
Australia
Prior art keywords
ile
asn
leu
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2019223130A
Other languages
English (en)
Other versions
AU2019223130A1 (en
Inventor
Geoffrey MASUYER
Pål STENMARK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toxotech AB
Original Assignee
Toxotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxotech AB filed Critical Toxotech AB
Publication of AU2019223130A1 publication Critical patent/AU2019223130A1/en
Application granted granted Critical
Publication of AU2019223130B2 publication Critical patent/AU2019223130B2/en
Priority to AU2024227611A priority Critical patent/AU2024227611A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019223130A 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid Expired - Fee Related AU2019223130B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227611A AU2024227611A1 (en) 2018-02-26 2024-10-24 Botulinum neurotoxin biohybrid

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1850213-8 2018-02-26
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain
PCT/EP2019/054310 WO2019162376A1 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227611A Division AU2024227611A1 (en) 2018-02-26 2024-10-24 Botulinum neurotoxin biohybrid

Publications (2)

Publication Number Publication Date
AU2019223130A1 AU2019223130A1 (en) 2020-09-10
AU2019223130B2 true AU2019223130B2 (en) 2024-07-25

Family

ID=65576340

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019223130A Expired - Fee Related AU2019223130B2 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
AU2024227611A Abandoned AU2024227611A1 (en) 2018-02-26 2024-10-24 Botulinum neurotoxin biohybrid

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227611A Abandoned AU2024227611A1 (en) 2018-02-26 2024-10-24 Botulinum neurotoxin biohybrid

Country Status (16)

Country Link
US (2) US20200407702A1 (https=)
EP (1) EP3759124A1 (https=)
JP (2) JP7458999B2 (https=)
KR (1) KR20200127175A (https=)
CN (1) CN111819189A (https=)
AU (2) AU2019223130B2 (https=)
BR (1) BR112020017323A2 (https=)
CA (1) CA3088928A1 (https=)
CL (1) CL2020002186A1 (https=)
IL (1) IL276930A (https=)
MX (1) MX2020008834A (https=)
MY (1) MY202690A (https=)
PH (1) PH12020551270A1 (https=)
SE (1) SE542539C2 (https=)
SG (1) SG11202006730SA (https=)
WO (1) WO2019162376A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
EP4093434A4 (en) * 2020-01-21 2024-06-26 Trustees of Dartmouth College Immunologically optimized botulinum toxin light chain variants
CN111675754A (zh) * 2020-05-19 2020-09-18 四川一埃科技有限公司 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法
CN114957482B (zh) * 2021-02-26 2024-09-24 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219837B (zh) * 2010-05-20 2013-10-30 中国人民解放军军事医学科学院微生物流行病研究所 重组全长a型肉毒毒素突变体疫苗
SG10201606666XA (en) * 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
US11242515B2 (en) 2016-05-16 2022-02-08 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
CN109476713A (zh) 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素

Also Published As

Publication number Publication date
CA3088928A1 (en) 2019-08-29
SE542539C2 (en) 2020-06-02
RU2020131317A (ru) 2022-03-29
IL276930A (en) 2020-10-29
CL2020002186A1 (es) 2020-12-28
MY202690A (en) 2024-05-15
SE1850213A1 (en) 2019-08-27
KR20200127175A (ko) 2020-11-10
CN111819189A (zh) 2020-10-23
JP7458999B2 (ja) 2024-04-01
WO2019162376A1 (en) 2019-08-29
JP2024069606A (ja) 2024-05-21
US20200407702A1 (en) 2020-12-31
AU2024227611A1 (en) 2024-11-14
JP2021514674A (ja) 2021-06-17
BR112020017323A2 (pt) 2020-12-29
AU2019223130A1 (en) 2020-09-10
SG11202006730SA (en) 2020-08-28
US20250034540A1 (en) 2025-01-30
MX2020008834A (es) 2021-01-08
EP3759124A1 (en) 2021-01-06
PH12020551270A1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
AU2019223130B2 (en) Botulinum neurotoxin biohybrid
AU2018200409B2 (en) Engineered botulinum neurotoxin
Kumaran et al. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation
AU2007226657B2 (en) Multivalent Clostridial toxins
AU2007347781B2 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US8623999B2 (en) Modified Clostridial toxins with enhanced targeting capabilities for endogenous Clostridial toxin receptor systems
JP2009513118A (ja) ボツリヌス神経毒ａタンパク質受容体およびその使用
RU2816855C2 (ru) Биогибрид ботулинического нейротоксина
WO2021190987A1 (en) Engineered botulinum neurotoxin serotype e
HK1260730A1 (en) Engineered botulinum neurotoxin
HK1260730B (en) Engineered botulinum neurotoxin

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee